Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study to Evaluate the Safety of FluMist in Healthy Children and Healthy Adults
NCT00113880 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study was to expand the data describing the safety profile of FluMist in the indicated populations (5-8, 9-17, and 18-49 years of age) and to assess the safety of annual revaccination in those who received FluMist in 2 or more consecutive years.
Conditions Studied
Interventions
- BIOLOGICAL FluMist
Study Locations (20)
California
- Kaiser Permanente Pediatrics — Alameda
- Kaiser Permanente Pediatrics — Antioch
- Kaiser Permanente Pediatrics — Clovis
- Kaiser Permanente Pediatrics — Daly City
- Kaiser Permanente — Davis
- Kaiser Pediatric Injections — Fairfield
- Kaiser Permanente-Pediatrics — Folsom
- Kaiser Permanente Adult Injection — Fremont
- Kaiser Permanente Pediatrics — Fremont
- Kaiser Permanente Pediactrics — Fresno
- Kaiser Permanente Pediatrics — Gilroy
- Kaiser Pediatric Injection Station — Hayward
- Kaiser Permanente — Lincoln
- Kaiser Pediatric Injection Station — Livermore
- Kaiser Permanente Injection Clinic — Manteca
- Kaiser Permanente Pediatrics — Martinez
- Kaiser Permanente Adult Medicine — Milpitas
- Kaiser Permanente Employee Health — Milpitas
- Kaiser Permanente Pediatrics — Milpitas
- Kaiser Permanente Injection Clinic — Modesto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63,061 participants |
| Start Date | 2003-10 |
| Est. Completion | 2010-06 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00113880
The ClinicalTrials.gov registry entry for NCT00113880 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 63,061 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 55 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention — of which FluMist is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00113880 reports 20 study locations spanning 1 distinct geographic area — top geographies include California. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00113880 about?
NCT00113880 is a clinical study titled "A Study to Evaluate the Safety of FluMist in Healthy Children and Healthy Adults". The purpose of this study was to expand the data describing the safety profile of FluMist in the indicated populations (5-8, 9-17, and 18-49 years of age) and to assess the safety of annual revaccination in those who received FluMist in 2 or more consecutive years.
What is the current status of trial NCT00113880?
This trial is currently completed. The enrollment target is 63,061 participants. The study started on 2003-10. Estimated completion is 2010-06.
What conditions does trial NCT00113880 study?
This clinical trial studies the following conditions: Healthy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00113880?
The interventions under investigation include: FluMist (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00113880?
This trial is sponsored by MedImmune, which has 55 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00113880 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.